MLchartDataset catalogue

allogeneic anti-CD20 CAR T cells LUCAR-20S

Term · Oncology and biomedicine · MLC-T-ONC-009812

A preparation of donor-derived T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD20 (cluster of differentiation 20), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-CD20 CAR T cells LUCAR-20S specifically recognize and kill CD20-expressing tumor cells. The CD20 antigen, a non-glycosylated cell surface phosphoprotein, is a B-cell-specific cell surface antigen expressed in B-cell lineage malignancies.

Table 1. Record
IdentifierMLC-T-ONC-009812
FieldOncology and biomedicine
SynonymsLUCAR-20S CAR-T cells
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-009812",
  "term": "allogeneic anti-CD20 CAR T cells LUCAR-20S",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of donor-derived T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD20 (cluster of differentiation 20), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-CD20 CAR T cells LUCAR-20S specifically recognize and kill CD20-expressing tumor cells. The CD20 antigen, a non-glycosylated cell surface phosphoprotein, is a B-cell-specific cell surface antigen expressed in B-cell lineage malignancies.",
  "synonyms": [
    "LUCAR-20S CAR-T cells"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/allogeneic-anti-cd20-car-t-cells-lucar-20s/"
}

Record 697 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.